Skip to Content

Medications for Non-Small Cell Lung Cancer

Other names: Cancer, Lung, Non-Small Cell; Lung Cancer, Non-Small Cell; NSCLC

Non-Small Cell Lung Cancer is cancer of the lung which is not small cell carcinoma.

Drugs used to treat Non-Small Cell Lung Cancer

The following list of medications are in some way related to, or used in the treatment of this condition.

Drug name Rating Reviews Activity ? Rx/OTC Pregnancy CSA Alcohol
ramucirumab Rate Add review
Rx C N

Generic name: ramucirumab systemic

Brand name:  Cyramza

Drug class: VEGF/VEGFR inhibitors

For consumers: dosage, interactions, side effects

For professionals: A-Z Drug Facts, AHFS DI Monograph

Rozlytrek Rate Add review
Rx N

Generic name: entrectinib systemic

Drug class: multikinase inhibitors

For consumers: dosage, interactions, side effects

For professionals: Prescribing Information

Tafinlar Rate Add review
Rx D N

Generic name: dabrafenib systemic

Drug class: multikinase inhibitors

For consumers: dosage, interactions, side effects

For professionals: Prescribing Information

cyclophosphamide Off-label Rate Add review
Rx D N

Generic name: cyclophosphamide systemic

Drug class: alkylating agents

For consumers: dosage, interactions, side effects

For professionals: A-Z Drug Facts, AHFS DI Monograph, Prescribing Information

Off-label: Yes

dabrafenib Rate Add review
Rx D N

Generic name: dabrafenib systemic

Brand name:  Tafinlar

Drug class: multikinase inhibitors

For consumers: dosage, interactions, side effects

For professionals: A-Z Drug Facts, AHFS DI Monograph

Infugem Rate Add review
Rx D N

Generic name: gemcitabine systemic

Drug class: antimetabolites

For consumers: dosage, interactions, side effects

For professionals: Prescribing Information

Mvasi Rate Add review
Rx C N

Generic name: bevacizumab systemic

Drug class: VEGF/VEGFR inhibitors

For consumers: dosage, interactions, side effects

For professionals: Prescribing Information

necitumumab 10 1 review
Rx N

Generic name: necitumumab systemic

Brand name:  Portrazza

Drug class: EGFR inhibitors

For consumers: dosage, interactions, side effects

For professionals: A-Z Drug Facts, AHFS DI Monograph

Portrazza Rate Add review
Rx N

Generic name: necitumumab systemic

Drug class: EGFR inhibitors

For consumers: dosage, interactions, side effects

For professionals: Prescribing Information

capmatinib Rate Add review
Rx N

Generic name: capmatinib systemic

Brand name:  Tabrecta

Drug class: multikinase inhibitors

For consumers: dosage, interactions, side effects

For professionals: A-Z Drug Facts, AHFS DI Monograph

cemiplimab Rate Add review
Rx N

Generic name: cemiplimab systemic

Brand name:  Libtayo

Drug class: anti-PD-1 monoclonal antibodies

For consumers: dosage, interactions, side effects

For professionals: A-Z Drug Facts, AHFS DI Monograph

dacomitinib Rate Add review
Rx N

Generic name: dacomitinib systemic

Brand name:  Vizimpro

Drug class: EGFR inhibitors, HER2 inhibitors

For consumers: dosage, interactions, side effects

For professionals: A-Z Drug Facts, AHFS DI Monograph

entrectinib Rate Add review
Rx N

Generic name: entrectinib systemic

Brand name:  Rozlytrek

Drug class: multikinase inhibitors

For consumers: dosage, interactions, side effects

For professionals: A-Z Drug Facts, AHFS DI Monograph

Libtayo Rate Add review
Rx N

Generic name: cemiplimab systemic

Drug class: anti-PD-1 monoclonal antibodies

For consumers: dosage, interactions, side effects

For professionals: Prescribing Information

Lumakras Rate Add review
Rx U

Generic name: sotorasib systemic

For consumers:

For professionals: Prescribing Information

Pemfexy Rate Add review
Rx D N

Generic name: pemetrexed systemic

Drug class: antimetabolites

For consumers: dosage, interactions, side effects

pralsetinib Rate Add review
Rx N

Generic name: pralsetinib systemic

Brand name:  Gavreto

Drug class: multikinase inhibitors

For consumers: dosage, interactions, side effects

For professionals: A-Z Drug Facts, AHFS DI Monograph

selpercatinib 10 1 review
Rx N

Generic name: selpercatinib systemic

Brand name:  Retevmo

Drug class: multikinase inhibitors

For consumers: dosage, interactions, side effects

For professionals: A-Z Drug Facts, AHFS DI Monograph

Tabrecta Rate Add review
Rx N

Generic name: capmatinib systemic

Drug class: multikinase inhibitors

For consumers: dosage, interactions, side effects

For professionals: Prescribing Information

Tepmetko Rate Add review
Rx N

Generic name: tepotinib systemic

Drug class: multikinase inhibitors

For consumers: dosage, interactions,

For professionals: Prescribing Information

tepotinib Rate Add review
Rx N

Generic name: tepotinib systemic

Brand name:  Tepmetko

Drug class: multikinase inhibitors

For consumers: dosage, interactions,

trametinib Rate Add review
Rx D N

Generic name: trametinib systemic

Brand name:  Mekinist

Drug class: multikinase inhibitors

For consumers: dosage, interactions, side effects

For professionals: A-Z Drug Facts, AHFS DI Monograph

Vizimpro Rate Add review
Rx N

Generic name: dacomitinib systemic

Drug class: EGFR inhibitors, HER2 inhibitors

For consumers: dosage, interactions, side effects

For professionals: Prescribing Information

Zirabev Rate Add review
Rx C N

Generic name: bevacizumab systemic

Drug class: VEGF/VEGFR inhibitors

For consumers: dosage, interactions, side effects

For professionals: Prescribing Information

Learn more about Non-Small Cell Lung Cancer

IBM Watson Micromedex

Symptoms and treatments

Drugs.com Health Center

Legend

Rating For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).
Activity Activity is based on recent site visitor activity relative to other medications in the list.
Rx Prescription Only.
OTC Over the Counter.
Rx/OTC Prescription or Over the Counter.
Off-label This medication may not be approved by the FDA for the treatment of this condition.
EUA An Emergency Use Authorization (EUA) allows the FDA to authorize unapproved medical products or unapproved uses of approved medical products to be used in a declared public health emergency when there are no adequate, approved, and available alternatives.
Pregnancy Category
A Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).
B Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
C Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.
D There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.
X Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use in pregnant women clearly outweigh potential benefits.
N FDA has not classified the drug.
Controlled Substances Act (CSA) Schedule
M The drug has multiple schedules. The schedule may depend on the exact dosage form or strength of the medication.
U CSA Schedule is unknown.
N Is not subject to the Controlled Substances Act.
1 Has a high potential for abuse. Has no currently accepted medical use in treatment in the United States. There is a lack of accepted safety for use under medical supervision.
2 Has a high potential for abuse. Has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Abuse may lead to severe psychological or physical dependence.
3 Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence.
4 Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3.
5 Has a low potential for abuse relative to those in schedule 4. Has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 4.
Alcohol
X Interacts with Alcohol.

Browse Treatment Options

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.